Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Size, Value And Growth Trajectory Through 2030
The ribonucleic acid (rna) therapy clinical trials market has shown consistent expansion recently. Its size is projected to increase from $2.7 billion in 2025 to $2.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.8%. Historically, this growth can be linked to factors such as limited rna-based therapeutic alternatives, the high expenses of initial clinical trials, hurdles in obtaining regulatory approvals, insufficient understanding of rna therapies, and a dependence on conventional treatment methods.
The ribonucleic acid (rna) therapy clinical trials market size is anticipated to demonstrate steady expansion in the coming years. It is projected to increase to $3.4 billion in 2030, achieving a compound annual growth rate (CAGR) of 4.7%. This growth over the forecast period can be attributed to enhancements in rna delivery technologies, increased funding for rare disease and anticancer research, strengthening collaboration between biotech and pharma companies, the growing adoption of personalized medicine approaches, and the broadening of global clinical trial networks. Prominent trends for the forecast period include a rising number of rna therapy clinical trials across diverse therapeutic areas, an intensified focus on rare disease and anticancer rna therapeutics, the expansion of mRNA vaccine and self-amplifying rna therapy trials, the integration of CRISPR and rna editing-based therapy trials, and the incorporation of advanced delivery platforms along with oligonucleotide conjugates.
Get A Free Sample Report With In-Depth Market Insights:
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Growth Catalysts And Demand Drivers
The expanding impact of infectious diseases is projected to drive the expansion of the ribonucleic acid (RNA) therapy clinical trials market in the future. These diseases are conditions resulting from pathogenic microorganisms like bacteria, viruses, fungi, or parasites that enter the body, reproduce, and compromise health. A primary factor contributing to the increase in infectious diseases is the surge in worldwide travel, enabling swift dissemination of pathogens across different areas and populations. Ribonucleic acid (RNA) therapy clinical trials play a role in combating infectious diseases by facilitating the creation and assessment of specific treatments capable of rapidly adjusting to new pathogens. For instance, in April 2025, a report from the Minnesota Department of Health, a US-based state agency, highlighted that in 2024, the percentage of HIV cases among males aged 35 to 39 saw an increase from 10% in 2023 to 17%. Consequently, the growing prevalence of infectious diseases is fueling the expansion of the ribonucleic acid (RNA) therapy clinical trials market.
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Segments: Where Is Growth Concentrated?
The ribonucleic acid (rna) therapy clinical trials market covered in this report is segmented –
1) By Modality: Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
2) By Clinical Trials Phase: Phase I, Phase II, Phase III, Phase IV
3) By Therapeutic Areas: Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
Subsegments:
1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
5) By Non-Antisense: RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Trends Shaping Long-Term Demand
Leading companies in the ribonucleic acid (RNA) therapy clinical trials market are concentrating on creating novel approaches, such as studies involving RNA-based antisense oligonucleotide therapy, to home in on particular genetic sequences, regulate gene expression, and deliver highly accurate treatments for both genetic and rare conditions. An RNA-based antisense oligonucleotide therapy clinical trial examines the application of brief synthetic RNA strands designed to attach to specific messenger RNA targets, with the goal of altering gene expression and addressing genetic ailments. For example, in December 2024, the French biotechnology firm Sepul Bio commenced the LUNA Phase 2b clinical trial. This trial aims to assess ultevursen, an RNA-based antisense oligonucleotide therapy, which targets mutations in exon 13 of the USH2A gene responsible for retinitis pigmentosa (RP) and Usher syndrome type 2a. This study is a two-year, double-masked, randomized, sham-controlled investigation planned to recruit 81 adults and children aged eight and above from various sites globally. The therapy is intended for patients diagnosed with RP or non-syndromic RP resulting from exon 13 mutations in USH2A, verifiable through genetic testing. The initiation of the LUNA trial follows encouraging outcomes from preceding Phase 1/2 studies, where ultevursen demonstrated improvements in visual acuity, retinal sensitivity, and retinal structure.
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Key Participants And Competitive Landscape
Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.
View The Full Ribonucleic Acid (RNA) Therapy Clinical Trials Market Report:
Ribonucleic Acid (RNA) Therapy Clinical Trials Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
